MGNX stock forecast
Our latest prediction for MacroGenics, Inc.'s stock price was made on the March 5, 2018 when the stock price was at 31.00$.
In the short term (2weeks), MGNX's stock price should underperform the market by -0.53%. During that period the price should oscillate between -8.18% and +8.53%.
In the medium term (3months), MGNX's stock price should underperform the market by -1.98%. During that period the price should oscillate between -17.75% and +21.56%.Get email alerts
Create a solid portfolio with MGNX
About MacroGenics, Inc.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
At the moment the company generates 68M USD in revenues.
On its last earning announcement, the company reported a loss of -3.08$ per share.
The book value per share is 7.39$
Three months stock forecastMarch 5, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|